Technology Bundle ID
TAB-2670

Intranasal Dry Powder Inhaler for Improved Delivery of Vaccines and Therapeutics

Linked ID
E-258-2013-0
Lead Inventors
Mark Papania (CDC)
Co-Inventors
Darin Knaus (Creare LLC)
Edward Moynihan (Creare LLC)
Eric Friets (Creare LLC)
James Barry (Creare LLC)
Mark Bagley (Creare LLC)
Development Stages
Prototype
Development Status
  • In vitro data available
  • Prototype
ICs
CDC
This Intranasal Dry Powder Inhaler (DPI), developed with Creare, Inc., allows low-cost delivery of powder vaccines. Nasal delivery has numerous advantages compared to traditional injected vaccines, including: 1) safe, needle-less administration by minimally-trained staff or patient; 2) better protection due to mucosal and cross-protection; and 3) decreased biohazard waste. Further, dry powder aerosol vaccine delivery is superior to liquid aerosol delivery in a number of ways, including: 1) no dose reconstitution required; 2) highly thermostable and may not need cold chain storage; 3) costs less to store and transport; 4) improved efficacy through elimination of liquid spray nasal-dripping. This CDC-Creare invention is unique in that it is inexpensive and suitable for single-use applications, such as vaccination. It prevents the dose being deposited within the lower respiratory tract, improving safety. This delivery system has a broad range of potential applications including, but not limited to, childhood vaccination programs, self-administered therapeutics, and emergency biodefense.
Commercial Applications
  • Intranasal delivery of vaccines and therapeutics
  • Childhood vaccination programs, mass immunization campaigns, or response to epidemics
Competitive Advantages
  • Safe, needle-less delivery
  • Allows self-administration
  • Improved protection via intranasal immunization
  • Decreased biohazard waste
  • Dose reconstitution is not required
  • Highly thermostable and may not need cold chain storage
  • Cost-effective
  • Primate study with a thermostable measles vaccine expected in the next year

Request More Info

Licensing Contact: